001446761 000__ 03836cam\a2200493Ii\4500
001446761 001__ 1446761
001446761 003__ OCoLC
001446761 005__ 20230310004016.0
001446761 006__ m\\\\\o\\d\\\\\\\\
001446761 007__ cr\un\nnnunnun
001446761 008__ 220519s2022\\\\sz\a\\\\o\\\\\000\0\eng\d
001446761 019__ $$a1317836590$$a1318990083
001446761 020__ $$a9783030963767$$q(electronic bk.)
001446761 020__ $$a3030963764$$q(electronic bk.)
001446761 020__ $$z9783030963750$$q(print)
001446761 020__ $$z3030963756
001446761 0247_ $$a10.1007/978-3-030-96376-7$$2doi
001446761 035__ $$aSP(OCoLC)1319037529
001446761 040__ $$aGW5XE$$beng$$erda$$epn$$cGW5XE$$dYDX$$dEBLCP$$dOCLCF$$dUKAHL$$dOCLCQ
001446761 049__ $$aISEA
001446761 050_4 $$aRC271.I45
001446761 08204 $$a616.99/406$$223/eng/20220519
001446761 24500 $$aCancer immunotherapies :$$bsolid tumors and hematologic malignancies /$$cPriya Hays, editors.
001446761 264_1 $$aCham, Switzerland :$$bSpringer,$$c2022.
001446761 300__ $$a1 online resource (xvi, 315 pages) :$$billustrations (some color).
001446761 336__ $$atext$$btxt$$2rdacontent
001446761 337__ $$acomputer$$bc$$2rdamedia
001446761 338__ $$aonline resource$$bcr$$2rdacarrier
001446761 4901_ $$aCancer treatment and research,$$x2509-8497 ;$$vvolume 183
001446761 5050_ $$aDevelopment of Cancer Immunotherapies -- Melanoma -- Engaging pattern recognition receptors in solid tumors to generate systemic anti-tumor immunity -- Allogeneic tumor antigen-specific T cells for broadly applicable adoptive cell therapy of cancer -- Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma -- Lag3: From Bench to Bedside -- Immunotherapy in Genitourinary Malignancy: evolution in revolution or revolution in evolution -- Immune-based therapeutic interventions for Acute Myeloid Leukemia.-Off-the-shelf chimeric antigen receptor immune cells from human pluripotent stem cells -- The single-cell level perspective of the tumor microenvironment and its remodeling by CAR-T cells -- Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematological Malignancies.
001446761 506__ $$aAccess limited to authorized users.
001446761 520__ $$aThis book presents the clinical scope of cancer immunotherapeutic agents for solid tumors and Hematologic malignancies, elaborates on the scientific details of their modes of action, and presents the impact of these agents on oncology, patients and the broader healthcare system. At present, cancer immunotherapies fall broadly into three categories: immune checkpoint inhibitors (ICIs), adoptive T cell therapies, and cancer vaccines which have distinct mechanisms of action. Immune checkpoint inhibitors rely upon disrupting tumor antigen recognition as self by the immune system through inhibition of checkpoint molecules. Adoptive T cell therapies involve the engineering of T cells ex vivo to target and destroy tumor cells. The first part of this book will provide an overview of the discovery and mechanistic details of the technology. The second part will be devoted to elaborating on the clinical outcomes, successes and limitations for specific tumor subtypes, which includes both solid tumors and hematologic malignances for both pediatric and adult populations. As such, the book offers a valuable resource for oncologists, hematologists, and all those seeking an up-to-date overview of cancer immunotherapies.
001446761 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed May 19, 2022).
001446761 650_0 $$aCancer$$xImmunotherapy.
001446761 655_0 $$aElectronic books.
001446761 7001_ $$aHays, Priya,$$d1968-$$eeditor.
001446761 77608 $$iPrint version: $$z3030963756$$z9783030963750$$w(OCoLC)1292588598
001446761 830_0 $$aCancer treatment and research ;$$vv. 183.$$x2509-8497
001446761 852__ $$bebk
001446761 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-030-96376-7$$zOnline Access$$91397441.1
001446761 909CO $$ooai:library.usi.edu:1446761$$pGLOBAL_SET
001446761 980__ $$aBIB
001446761 980__ $$aEBOOK
001446761 982__ $$aEbook
001446761 983__ $$aOnline
001446761 994__ $$a92$$bISE